TAK-881

N/A

Report date: 2026/04/09 20:00:21

Base Information

Drug NameTAK-881
Drug Alias Namemmune Globulin Subcutaneous (Human), 20% Solution With Recombinant Human HyaluronidaseTAK-881
ClassificationBiologics > Blood components
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsPrimary Immunodeficiency DiseasesPolyradiculoneuropathy, Chronic Inflammatory Demyelinating
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesSlovakia +[13] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTakeda Development Center Americas IncBaxalta Innovations Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharms NaBaxalta Innovations GmbhTakeda Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsPrimary Immunodeficiency DiseasesPolyradiculoneuropathy, Chronic Inflammatory Demyelinating
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A